<DOC>
	<DOCNO>NCT00950365</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell , even shrink tumor patient , block enzyme epidermal growth factor receptor ( EGFR ) need cell growth spread . Pemetrexed drug inhibits several key protein require folic acid synthesize DNA . Blocking DNA synthesis tumor cell show decrease tumor growth . block tumor growth different way . Giving erlotinib together pemetrexed specific schedule may kill tumor cell give pemetrexed . PURPOSE : This phase I/II trial study side effect best dose erlotinib cetuximab see well work treat patient advance solid tumor progressive recurrent stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Pharmacodynamic Separation Pemetrexed Erlotinib Second-line Therapy Patients With Advanced Non-small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must histologically cytologically confirm advanced ( Stage IIIB malignant pleural effusion Stage IV disease ) recurrent nonsquamous NSCLC . Patients must least one measurable disease per RECIST criterion Patient must disease progression one prior chemotherapy and/or target therapy pemetrexed antiEGFR therapy metastatic disease , relapse receive adjuvant therapy , within 12 month complete adjuvant therapy Patients immunotherapy , hormone , chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . Patients uncontrolled brain metastasis exclude clinical trial poor prognosis . Patients immune deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>progressive recurrent stage III stage IV non-small cell lung cancer</keyword>
</DOC>